The name of the company has been changed from Laurel Organics Limited to Kimia Biosciences Limited with effect from 04-01-2019 pursuant to the Scheme of Arrangement for Amalgamation of Kimia Biosciences Limited-Transferor Company-with Laurel Organics Limited -Transferee Company-as per the approval and Order of Honrable NCLT Chandigarh.
+91-11-4706 3600
info@kimiabiosciences.com

Research & Development:

(Approved by Department of Scientific & Industrial Research, (DSIR))

Kimia Biosciences R&D is committed to research and development of improved generic drugs with the goal of addressing unmet patient needs with more meticulous resources and to establish a robust portfolio for a new generation of treatments. Kimia is committed to do significant investments in drug research and development in order to produce effective, safe and affordable medicines.

Infrastructure:

Kimia R&D has well equipped Analytical Lab, synthetic Lab and Intellectual property cell, where each scientist has access to Sci-finder search tools. The Analytical Research lab comprises of HPLC, GC, GC-HS, Auto-Titrator, Polarimeter, UV spectrophotometer, IR spectrophotometer etc. There are dedicated hoods for each scientist in the synthetic lab with Rotavapours, Vacuum & Air dryers, cooling units, mechanical and magnetic stirrers, vacuum systems Instrumentation, scientific and analytical knowledge base at the R&D Centre facilitate:

  • Impurity profiling for the APIs
  • Development of Analytical methods and their validations
  • Specifications from Raw materials to Non-pharmacopoeia Finished products.
  • Accelerated and Real time stability studies

Expertise:

The expertise of R&D teams covers products across various therapeutic categories including Ant diabetics & Anti-hypertensive.


  • Chiral chemistry
  • Synthesizing building blocks
  • Reactions: Pressure, Cryogenic, Metal hydride,Catalytic, Aliphatic-Aromatic-Heterocyclic, & Multi-step synthesis,
  • Polymorphism
  • Particle Size
  • Bulk density
  • Impurities synthesis
  • Quality by Design approach
  • DOE

Culture:

We are committed to create a culture of respect and dignity of each individual based on humanistic values at Kimiabiosciences where the individuality of each person is respected

Speed:

Kimia strives hard and give their best to help meet customer deadlines with ICH quality products; the average time todevelop a process technology is 6-8 months

Innovation:

  • Chiral reductions using homogeneous catalyst
  • Chiral reduction using Enzymatic Technologies,
  • Polymorphs Processes and Techniques,
  • Process innovations to achieve benchmark costs

Patents

TNo. of patent applications filed: 4

R&D Scientists:

The team of Scientists at Kimia R&D involves people from diverse backgrounds who uses their vast experience & innovativeness and are determined to make Kimia R&D as an advance Centre for Research.

Quality

The Kimia R&D is committed to produce drugs of high quality based on principles of quality by design and ICH requirements

New products developed:

  • Prucalopride succinate
  • Azelnidipine
  • Acotiamide Hydrochloride trihydrate
  • Vildagliptin
  • Fimasartan Potassium Hydrate